Bruker Corporation (NASDAQ:BRKR) Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue reduced its holdings in Bruker Corporation (NASDAQ:BRKR - Free Report) by 69.5% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 12,949 shares of the medical research company's stock after selling 29,522 shares during the quarter. State of Alaska Department of Revenue's holdings in Bruker were worth $540,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in BRKR. London Co. of Virginia boosted its stake in Bruker by 78.4% during the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock valued at $245,820,000 after buying an additional 1,843,294 shares in the last quarter. Brown Advisory Inc. boosted its stake in Bruker by 10.1% during the 4th quarter. Brown Advisory Inc. now owns 2,026,712 shares of the medical research company's stock valued at $118,806,000 after purchasing an additional 185,912 shares during the period. Geode Capital Management LLC raised its holdings in shares of Bruker by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 2,013,741 shares of the medical research company's stock worth $118,081,000 after buying an additional 20,273 shares in the last quarter. FIL Ltd grew its holdings in shares of Bruker by 262.3% in the 4th quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock worth $114,978,000 after purchasing an additional 1,420,102 shares during the last quarter. Finally, Sculptor Capital LP raised its position in Bruker by 484.1% in the 4th quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company's stock valued at $100,476,000 after purchasing an additional 1,420,569 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Insider Transactions at Bruker

In other Bruker news, CEO Frank H. Laukien bought 2,608 shares of Bruker stock in a transaction that occurred on Friday, June 6th. The shares were bought at an average price of $38.36 per share, with a total value of $100,042.88. Following the acquisition, the chief executive officer now owns 38,462,171 shares in the company, valued at approximately $1,475,408,879.56. This trade represents a 0.01% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 27.30% of the company's stock.

Bruker Price Performance

Shares of BRKR opened at $41.80 on Monday. The business's 50 day moving average price is $38.52 and its two-hundred day moving average price is $46.41. Bruker Corporation has a 52-week low of $34.10 and a 52-week high of $72.94. The firm has a market cap of $6.33 billion, a PE ratio of 80.38, a price-to-earnings-growth ratio of 2.81 and a beta of 1.16. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.74 and a current ratio of 1.57.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.01. Bruker had a net margin of 2.31% and a return on equity of 19.47%. The business had revenue of $801.40 million for the quarter, compared to analysts' expectations of $763.83 million. During the same quarter last year, the firm earned $0.53 EPS. The firm's revenue for the quarter was up 11.0% compared to the same quarter last year. On average, equities analysts anticipate that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Monday, June 16th were paid a $0.05 dividend. The ex-dividend date was Monday, June 16th. This represents a $0.20 dividend on an annualized basis and a yield of 0.48%. Bruker's dividend payout ratio is 38.46%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on BRKR shares. Wells Fargo & Company cut their price target on Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a research note on Thursday, April 17th. Bank of America cut their price objective on Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a report on Thursday. UBS Group reduced their price objective on Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. Stifel Nicolaus cut their price target on Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a research note on Thursday, May 8th. Finally, Barclays decreased their price target on Bruker from $50.00 to $46.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Six analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $52.89.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.